Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 05/24 09:59:59 pm
86.22 USD   +3.47%
05/24DJGILEAD SCIENCES : Names New Operating Chief
05/24 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief ..
05/20 GILEAD SCIENCES : to Present at the UBS Global Healthcare Conference..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GILEAD SCIENCES, INC.
05/24DJGILEAD SCIENCES : Names New Operating Chief
05/24 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief Operating Of..
05/23 GILEAD SCIENCES : Breaking down barriers to HIV/Aids treatment – afternoon..
05/20 GILEAD SCIENCES : to Present at the UBS Global Healthcare Conference on Monday, ..
05/19 GILEAD SCIENCES : Patent Issued for Apoptosis Signal-Regulating Kinase Inhibitor..
05/19 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch Healthcare Con..
05/19 GILEAD SCIENCES : Findings in the Area of Respiratory Syncytial Virus Infections..
05/19 1986-1990
05/18 GILEAD SCIENCES : Breaking down barriers to HIV/Aids treatment – afternoon..
05/17 GILEAD SCIENCES : US drug maker Gilead Sciences withdrew a writ petition filed i..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials